The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.The ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

FRANKFURT (Reuters) - The CEO of Roche said more cases of mpox infection have likely occurred in Europe than previously ...

Roche Holding (RHHBF) reaffirms full-year sales and earnings outlook after its Q3 results exceeded Street forecasts. Read ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

This summer, I went to 36 independently-owned bookstores across the state of Iowa. From big cities like Des Moines and ...